<DOC>
	<DOCNO>NCT02246127</DOCNO>
	<brief_summary>The purpose study elucidate sequence streptozotocin ( STZ ) base chemotherapy mammalian Target Rapamycin ( mTOR ) inhibitor , everolimus , give good result term second Progression Free Survival ( PFS ) well differentiate advanced pancreatic NETs .</brief_summary>
	<brief_title>Efficacy Safety Everolimus ( STZ-5FU ) Given One Upfront Other Upon Progression Advanced pNET</brief_title>
	<detailed_description>STZ base chemotherapy , STZ-5FU , actual standard care advance pancreatic Neuroendocrine tumour ( pNETS ) European Union . Everolimus recently approve use advance pNETs Food Drug Administration ( FDA ) Europe European Medical Agency ( EMA ) . A randomized study need clear knowledge best sequence administration ; , palliative chemotherapy . There may may benefit give first treatment study . The information obtain study help physician improve treatment management patient advanced pNET .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven diagnosis unresectable metastatic , advanced pancreatic NET . Documented confirmation pancreatic NET G1 G2 per European Neuroendocrine Society ( ENETS ) classification system . Patients paraffinembedded primary tumour metastasis block available sent Courier . Before study inclusion , patient must show progressive disease document radiology 12 month prior study inclusion . Treatment naive patient also include patient need active treatment either chemotherapy everolimus . Presence measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 1.0 , document Triphasic Computed Tomography ( CT ) scan multiphase MRI radiological assessment . Previous treatment somatostatin ( SS ) analogues allow . Only patient active functioning syndrome entry continue SS analogue study . Adequate bone marrow renal function , serum fast cholesterol Women childbearing potential must negative serum pregnancy test . Written Informed Consent obtain accord local regulation Previous treatment chemotherapy and/or mTOR inhibitor tyrosine kinase inhibitor . Immune therapy radiation therapy within 4 week prior patient enter study . Hepatic artery embolization within last 6 month ( 1 month site measurable disease ) , cryoablation/radiofrequency ablation hepatic metastasis within 2 month enrolment . Previous treatment PeptideReceptor Radionuclide Therapy ( PRRT ) within last 6 month and/or without progression follow PRRT . Uncontrolled diabetes mellitus . Any severe and/or uncontrolled medical condition . Treatment potent inhibitor inducer Cytochrome P450 3A4 ( CYP3A ) isoenzyme within 5 day immediately start treatment . Patients chronic treatment corticosteroid immunosuppressive agent . Patients know HIV seropositive . Known intolerance hypersensitivity everolimus excipients rapamycin analogue . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption take medicinal product . Known intolerance hypersensitivity 5FU STZ excipients ( notice criterion include patient know deficit dihydropyrimidine dehydrogenase deficiency DPD ) . Pregnant , lactate woman fertile adult use effective birth control method . For administrative matter ( insurance ) patient â‰¥ 95 allow trial . Only patient come hospital pool include SEQTOR trial ( e.g . person detain institution result official court order exclude ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>94 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>advanced pNET</keyword>
	<keyword>everolimus</keyword>
	<keyword>STZ-5FU</keyword>
	<keyword>treatment sequence</keyword>
</DOC>